ArticleFrontiers in cellular and infection microbiology2026
Antibody screening identifies HERV-K-related immune responses as candidate biomarkers in Parkinson's disease.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is increasingly recognized as a disorder involving both neurodegenerative and immune-related mechanisms. To explore potential immune alterations associated with PD, we analyzed plasma antibody responses against a panel of viral and host synthetic linear epitopes in PD patients (n = 50) and healthy controls (HCs) (n = 54). Antibody levels against Interferon Regulatory Factor 5 (IRF5), Cathepsin B (CTSB), L-asparaginase (ASRGL1), Human Endogenous Retrovirus type K (HERV-K), Interferon-α (IFN-α), Interferon- ω (IFN-ω), α-synuclein, Herpes Simplex Virus type 1 (HSV-1), olfactory receptor proteins (OLF-R), and Dickkopf-related protein 3 (DKK3) were measured. PD patients showed significantly higher antibody levels against IRF5, CTSB, ASRGL1, and HSV-1 compared with controls, while antibodies against HERV-K were significantly lower. No differences were observed for IFN-α, IFN-ω, α-synuclein, OLF-R, or DKK3. Correlation analysis revealed several associations among antibody responses. IRF5 antibodies correlated positively with CTSB, ASRGL1, HERV-K, IFN-α, IFN-ω, and HSV-1. CTSB correlated with IFN-α, IFN-ω, HSV-1, OLF-R, and DKK3, while ASRGL1 correlated with HERV-K and IFN-ω. IFN-α correlated with IFN-ω, HSV-1, and DKK3, and IFN-ω correlated with HSV-1 and DKK3. HSV-1 antibodies were also associated with OLF-R and DKK3. Notably, HERV-K antibodies showed a negative correlation with DKK3. Stratification analyses indicated that antibody levels against HERV-K were higher in patients with milder disease stages accordingly with Hoehn and Yahr scale (HY 1-4) compared with HY 5, whereas IFN-α antibodies were increased in HY5 patients. Female patients generally showed lower antibody levels than males for different targets. No differences were observed according to disease duration. Overall, these findings indicate that PD patients display selective changes in antibody responses involving antiviral and host proteins. These targets may represent potential biomarkers of immune alterations in PD, although further studies are required to clarify the underlying biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.